Regencell Bioscience Holdings Limited (NASDAQ:RGC) Sees Significant Drop in Short Interest

Regencell Bioscience Holdings Limited (NASDAQ:RGC) saw a large drop in short interest in February. As of February 13th, there was short interest totaling 670,710 shares, a drop of 13.3% from the January 29th total of 773,634 shares. Approximately 0.1% of the shares of the company are short sold. Based on an average trading volume of 167,394 shares, the days-to-cover ratio is currently 4.0 days. Based on an average trading volume of 167,394 shares, the days-to-cover ratio is currently 4.0 days. Approximately 0.1% of the shares of the company are short sold.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings reiterated a “sell (e+)” rating on shares of Regencell Bioscience in a research note on Monday, December 29th. One analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, the stock currently has a consensus rating of “Sell”.

Hedge Funds Weigh In On Regencell Bioscience

A number of hedge funds have recently added to or reduced their stakes in the stock. Seven Fleet Capital Management LP purchased a new stake in shares of Regencell Bioscience in the fourth quarter worth approximately $92,000. Y Intercept Hong Kong Ltd purchased a new position in Regencell Bioscience during the second quarter worth about $222,000. Hudson Bay Capital Management LP bought a new stake in Regencell Bioscience in the 4th quarter worth about $275,000. XTX Topco Ltd purchased a new stake in Regencell Bioscience in the 3rd quarter valued at about $598,000. Finally, Vident Advisory LLC lifted its position in shares of Regencell Bioscience by 65.7% during the 4th quarter. Vident Advisory LLC now owns 29,934 shares of the company’s stock worth $629,000 after buying an additional 11,866 shares in the last quarter. Institutional investors and hedge funds own 0.13% of the company’s stock.

Regencell Bioscience Trading Up 2.9%

Shares of NASDAQ RGC traded up $0.70 during midday trading on Wednesday, hitting $24.69. 44,765 shares of the stock traded hands, compared to its average volume of 535,551. Regencell Bioscience has a one year low of $0.11 and a one year high of $83.60. The business has a 50 day moving average price of $28.98 and a two-hundred day moving average price of $19.98.

Regencell Bioscience Company Profile

Regencell Bioscience Holdings Limited operates a Traditional Chinese medicine (TCM) bioscience company. It focuses on the research, development, and commercialization of TCM for the treatment of neurocognitive disorders and degeneration, primarily attention deficit hyperactivity disorder and autism spectrum disorder. The company was incorporated in 2014 and is headquartered in Causeway Bay, Hong Kong.